liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
ReFerm®: a postbiotic fermented oat gruel composition is reducing mast cell degranulation in the colon of patients with irritable bowel syndrome
Linköping University, Department of Biomedical and Clinical Sciences, Division of Surgery, Orthopedics and Oncology. Linköping University, Faculty of Medicine and Health Sciences.ORCID iD: 0000-0002-6239-5269
Linköping University, Department of Health, Medicine and Caring Sciences, Division of Diagnostics and Specialist Medicine. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Mag- tarmmedicinska kliniken.ORCID iD: 0000-0002-3463-9705
Nord Rebalance AS, Denmark.
Linköping University, Department of Biomedical and Clinical Sciences, Division of Surgery, Orthopedics and Oncology. Linköping University, Faculty of Medicine and Health Sciences.
Show others and affiliations
2024 (English)In: Frontiers in Medicine, E-ISSN 2296-858X, Vol. 11, article id 1408623Article in journal (Refereed) Published
Abstract [en]

Background: Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disorder that affects similar to 4% of the global population. ReFerm((R)) is a postbiotic product derived from oat gruel fermented with Lactobacillus plantarum 299v, and it has been shown to have beneficial effects on intestinal permeability in patients with IBS. In this study, we investigated the effects of ReFerm((R)) on regulators of intestinal permeability, namely mast cells and enteric glial cells. Materials and methods: A total of 30 patients with moderate to severe IBS were treated with an enema containing ReFerm((R)) or a placebo twice daily. The patients underwent sigmoidoscopy with biopsies obtained from the distal colon at baseline and after 14 days of treatment. These biopsies were processed in two ways: some were fixed, embedded in paraffin, sectioned, and stained for mast cells and enteric glial cells; others were cryopreserved, lysed, and subjected to Western blotting to analyze the same markers. Results: Treatment with ReFerm((R)), but not the placebo, significantly reduced mast cell tryptase protein levels in the biopsy lysates. Although the number of mast cells remained unchanged in colonic biopsies, ReFerm((R)) treatment significantly reduced mast cell degranulation, a result not observed in the placebo group. Neither ReFerm((R)) or placebo treatment had an impact on total protein levels or the number of enteric glial cells in the biopsies. Conclusion: ReFerm((R)) treatment significantly reduced both total mast cell tryptase levels and the degranulation of mast cells in colonic biopsies from patients with IBS, suggesting a decrease in mast cell activity as a potential mechanism underlying the beneficial effects of ReFerm((R)). However, further research is required to assess the molecular mechanisms through which ReFerm((R)) operates in the colons of patients with IBS.

Place, publisher, year, edition, pages
FRONTIERS MEDIA SA , 2024. Vol. 11, article id 1408623
Keywords [en]
functional gastrointestinal disorder; postbiotics; intestinal permeability; mucosal immunology; enteric nervous system
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:liu:diva-206407DOI: 10.3389/fmed.2024.1408623ISI: 001272080200001PubMedID: 39026547OAI: oai:DiVA.org:liu-206407DiVA, id: diva2:1890260
Note

Funding Agencies|Linkpings Universitet10.13039/501100003945; Nordic Rebalance

Available from: 2024-08-19 Created: 2024-08-19 Last updated: 2025-04-15

Open Access in DiVA

fulltext(2432 kB)99 downloads
File information
File name FULLTEXT01.pdfFile size 2432 kBChecksum SHA-512
574df8f4d653c16025f9c8d56a78e338870ccfd27fd2be0e285cc6472e5c0011bba17d0d09d3ceea768684448859d5921f220f4654c052d5b06e09ff1828b834
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Biskou, OlgaWalter, SusannaWinberg, Martin E.Bednarska, OlgaKeita, Åsa V.
By organisation
Division of Surgery, Orthopedics and OncologyFaculty of Medicine and Health SciencesDivision of Diagnostics and Specialist MedicineMag- tarmmedicinska klinikenDivision of Inflammation and Infection
In the same journal
Frontiers in Medicine
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar
Total: 99 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 167 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf